Replies to post #393959 on NorthWest Biotherapeutics Inc (NWBO)

[jondoeuk]

Not for TIL. In 'cold' types, Dr. Rosenberg has reported an ORR of 12% using neoantigen reactive and it almost doubles with an added anti-PD-1 (up to four doses of Keytruda). With better selection (CD39-CD69-CD8+* and eventually certain CD4+ population(s)) and ex vivo expansion, the ORR should improve.

* Associated with complete responses https://science.sciencemag.org/content/370/6522/1328

[Horseb4CarT]

As the village idiot in Monty Python’s Flying Circus would say, “ muy head hurts” from trying to read all the medical jargon :-)